Natco Pharma News

Natco Pharma is exploring opportunities beyond generic drugs for future growth, as explained by CEO and Vice Chairman Rajeev Nannapaneni. He detailed how Indian

Natco Pharma has invested $14 million in the biotech firm eGenesis, bringing its total investment to $22 million. eGenesis is focused on developing genome-engin

Pharma stocks, specifically Caplin Point and Natco Pharma, are under scrutiny following U.S. FDA inspections that resulted in observations at their facilities.

Indian equity markets closed largely unchanged on Friday, August 21, with several companies like Reliance Industries and Bank of Baroda reporting significant co

Today is the last day to buy shares of Mazagon Dock, Natco Pharma, and 13 other stocks to be eligible for their dividends. Mazagon Dock Shipbuilders had announc

Natco Pharma reported a slump in its Q1 net profit and revenue, primarily due to lower sales of its cancer drug Lenalidomide, causing its shares to tumble.

Natco Pharma shares surged 5% after receiving tentative approval from the U.S. FDA for its generic Olaparib tablets, a bioequivalent version of AstraZeneca's Ly

Natco Pharma has increased its stake in South African company Adcock Ingram to 49%.